Riboksin-Darnitsa

General characteristics. Structure:

International and chemical names: Inosine; [9-D-ribofuranozil-hypoxanthine (hypoxanthine riboside)];
main physical and chemical properties: transparent, colourless liquid;
structure: 1 ml of solution contains 0,02 g of inosine (inosine); 
excipients: hexamethylenetetramine, 1 M solution of natron caustic, water for injections.

Pharmacological properties:

Inosine concerns to group of the anabolic substances stimulating metabolic processes. Derivative purine (nucleoside), predecessor of adenosinetriphosphate (ATP). Stimulates synthesis of nucleotides, increases activity of some enzymes of a tricarbonic acid cycle. Can get into myocardium cells, raising its energy level, shows weak antiarrhytmic action. Having positive effect on processes of exchange in the last, improves coronary circulation. Influences exchange processes in a liver, promotes synthesis of power and plastic material.

Pharmacokinetics. The first minutes at intravenous administration Riboksin-Darnitsa is metabolized and quickly distributed in fabrics.

Indications to use:

Riboksin-Darnitsa appoint for complex treatment of coronary heart disease, a myocardial dystrophy, at disturbances of the cordial rhythm including caused by use of cardiac glycosides. Use of drug is also shown for treatment of an urokoproporfiriya, hepatitises, liver cirrhoses. Improves visual functions at an open-angle form of glaucoma with normalized (by treatment by antihypertensives) intraocular pressure.

Route of administration and doses:

Riboksin-Darnitsa (solution for injections of 2%) appoint intravenously.
Intravenously enter slowly (40-60 drops 1 minute) kapelno or struyno. In the beginning enter 200 mg (10 ml of 2% of solution) once a day, into the subsequent terms at good tolerance - to 400 mg (20 ml of 2% of solution) 1-2 times a day. A course of treatment - 10-15 days.
Jet introduction is possible at acute disorders of a heart rhythm in a single dose of 200-400 mg (10-20 ml of 2% of solution).
At drop introduction to a vein of 2% solution of drug is dissolved in 5% solution of glucose or isotonic solution of sodium of chloride (to 250 ml).

Features of use:

At emergence of an itch and a dermahemia treatment by drug should be cancelled. During prolonged treatment it is desirable to control the level of uric acid in blood and urine.

Side effects:

At Riboksin-Darnits's use the individual intolerance which is shown an itch, a dermahemia is possible. Seldom at treatment of Riboksinom-Darnitsa concentration of uric acid in blood increases. The exacerbation of gout (prolonged use) is possible.

Interaction with other medicines:

At simultaneous introduction of Riboksin-Darnits with adrenoblockers Riboksin-Darnits's effect does not decrease. At combined use with cardiac glycosides drug can prevent developing of arrhythmias, strengthen positive inotropic action.

Contraindications:

Hypersensitivity, gout. Period of pregnancy and feeding by a breast. Restriction to administration of drug is the renal failure.

Overdose:

Strengthening of an itch, rash, exacerbation of gout is possible. Symptomatic treatment.

Storage conditions:

To store in protected from light and the place, unavailable to children, at a temperature from 15 to 25 °C.

Period of validity - 4 years.

Issue conditions:

According to the recipe

Packaging:

Solution for injections of 2% on 5 ml in ampoules No. 10, on 10 ml in ampoules No. 5, No. 10.